



Koios Mapping Human Brain to Study Impact of CBD

VANCOUVER, Nov. 8, 2018 /CNW/ - Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF:US) (the "**Company**" or "**Koios**"), is pleased to announce the Company will be initiating a clinical study into the impact of CBD on the human brain.

Koios is already conducting a clinical trial on the impact of its nootropic supplements on the human brain, and released preliminary results on Oct. 9, 2018. Koios beverages and supplements contain a proprietary formula of nootropic, brain-enhancing nutrients.

The trial involved mapping the activity of the brain before and after subjects consumed Koios nootropic supplements.

Full clinical brain scans on Koios users show changes in brain activity in three main areas, all of which indicate improved cognitive function.

"The findings, although preliminary, are better than we could have expected," said Chris Miller, CEO of the Company. "Changes in the type of brain activity that we are seeing between the baseline that was mapped at the start of the study, and the effect on participants after several months of consuming our beverages, could have many positive implications."

Vice President of Sales Gina Burrus says the results are helping the Company in the design of future products, and so Koios has decided to launch similar trials of nootropics with CBD.

"It's long been known that CBD can have a dramatic impact on the human brain, all the way from helping people relax to treating people for epilepsy," said Burrus. "However, we don't yet know what impact CBD will have when combined with nootropics, and that's what this study is designed to tell us."

Both studies are being conducted by NeuraPerformance/Neurooptimize Brain Center, the go-to brain lab and physiotherapy clinic for Colorado's elite athletes, including the Denver Broncos football team. The lab's brain-mapping technique involves using sensors to measure the electrical activity within the client's brain.

In the first study, the lab reported three initial findings of significance: a decrease in slow brain-wave activity, (delta and theta) which for many people "can lead to quicker thought processes, better energy, sharper focus and an overall sense of mind clarity," says Rachel Ragsdale, founder and CEO of Neurooptimize.

The second key finding was an increase in alpha activity, linked with overall intelligence. The third finding was an increase in fast activity (beta and high beta). "This brain wave is needed to feel alert, focused, and motivated," said Ragsdale, an accredited Board Certified Neurofeedback Therapist. "Seeing an increase in this brain wave could have many implications relating to the overall drive and energy of a person that might lack beta and is a very positive finding."

NeuraPerformance/Neurooptimize is expected to release a full report within the next month, after which it will begin further testing of nootropics and CBDs.

"We are a results-driven company," said Miller. "It's our hope that through these tests, we will learn

more about how to continually improve the mental and physical well-being of our customers."

On behalf of the Board of Directors of the Company.

KOIOS BEVERAGE CORP.

"Chris Miller"

Chris Miller, CEO and Director

About the Company's Business

The Company is an emerging functional beverage company which has an available distribution network of more than 2,000 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well. Koios is also the sole owner of Cannavated Beverage Corp., a subsidiary that develops beverage products and formulas for the growing cannabis market. Through its agreement with Keef Brands, the largest producer of cannabis beverages in North America, Cannavated enjoys distribution throughout the State of Colorado and is preparing for distribution in additional US states where cannabis use is legal.

Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants. Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity. Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.

Koios is one of the only drinks in the world to infuse its products with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: www.mentaltitan.com.

On behalf of the Board of Directors of the Company.

Forward Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding the timing for resumption of trading for the Company's stock. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

None of the studies conducted by Koios have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios's products will vary from person to person. No claims or guarantees can be made as to the effects of Koios's products on an individual's health and wellbeing.

SOURCE Koios Beverage Corp.

View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/November2018/08/c8344.html>

%SEDAR: 00033678E

For further information: Paula Arab, Media and Investor Relations Strategist,
paula.arab@koiosbeveragecorp.com

CO: Koios Beverage Corp.

CNW 11:01e 08-NOV-18